Breadcrumb Home Responsibility Access to Health Collaborative Research on a Rice-Based Oral Vaccine Collaborative Research on a Rice-Based Oral Vaccine Important Notice This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider. I Agree In June 2016, Astellas signed a new collaborative development agreement with the Institute of Medical Science, the University of Tokyo (IMSUT) on the rice-based oral vaccine “MucoRice-CTB” against diarrheal diseases caused by cholera and enterotoxigenic Escherichia coli (E.coli). In developing countries, diarrhea caused by pathogenic bacteria such as Vibrio cholerae and enterotoxigenic E.coli, is a major cause of death among infants and young children. However, existing cholera vaccines present several issues, including the need to store and transport the vaccines at a constant low temperature, and their ineffectiveness against enterotoxigenic E.coli. MucoRice-CTB is stable at room temperature and easily produced. Therefore, it is expected to meet the unmet medical needs of existing cholera vaccines. MucoRice-CTB is a rice-based oral vaccine expressing a cholera toxin B (CTB) subunit in the intrinsic storage protein of rice using genetic engineering. It was developed by Prof. Hiroshi Kiyono, Project Researcher Yoshikazu Yuki and their colleagues at the International Research and Development Center for Mucosal Vaccines, IMSUT. Under the agreement, IMSUT provides investigational medicines and study data, etc., which are necessary for phase 1 and 2 of clinical trials of MucoRice-CTB for cholera and enterotoxigenic E.coli, and Astellas is responsible for conducting and managing the clinical trials. Through this collaborative development, Astellas will work to develop vaccines against infectious diseases affecting developing countries. RESPONSIBILITY Our Commitment CSR-Based Management Stakeholder Communications CSR Activities in Five Fields Access to Health Access Accelerated Action on Fistula Development of Pediatric Formulation for Schistosomiasis Collaborative Research on a Rice-Based Oral Vaccine Collaborative Research to Discover Anti-protozoan Parasite Drugs The NTDs Drug-discovery Research Consortium GHIT Fund Awards & Recognition Main navigation About Message from CEO Philosophy Vision & Strategy Governance Corporate Information History Board of Directors Top Management Product Introductions Policies & Position Statements Astellas at a Glance Compliance Initiatives Innovation Therapeutic Areas R&D Partnering Responsibility Our Commitment CSR-Based Management Stakeholder Communications CSR Activities in Five Fields Access to Health Awards & Recognition News News Stories Media Contacts Investors Financial Information Stock & Rating Information IR Calendar IR Library Analyst Coverage Cautionary Statement Bottom footer menu SITE MAP PRIVACY POLICY ACCESSIBILITY TERMS OF USE CONTACT US Copyright © 2017 Astellas Pharma Inc. All Rights Reserved.